Home » Newsletters » BioWorld

BioWorld

Sep. 27, 1993

View Archived Issues

CELLCOR TO BEGIN ALT PROTOCOL

FOCAL REPORTS PRECLINIAL RESULTS

NEW DRUG HELPS RATS SHAKE THE SHAKES

SCICLONE SUES ALPHA 1

IDEXX SPLITS STOCK 2 FOR 1

PESTICIDE REFORM BRINGS GOOD NEWS FOR BIOTECH

NEOCRIN GARNERS $5M PRIVATELY

BIO GETS LOBBYING ADVICE

AUTOIMMUNE'S STOCK JUMPS

ORAL TOLERIZATION RELIEVES RA

BLOCK LICENSES AFFINITY PRODUCT

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 11, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 11, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...
DEE-lightful: Praxis’ phase II results allow stock to flex its muscle
BioWorld
Positive efficacy results led to Praxis Precision Medicines Inc.’s phase II Embold study in developmental and epileptic encephalopathies (DEEs) being halted...